Alok Khorana

Cleveland

Associate Editor at Cancer Investigation

Hardis Endowed Chair, FACP, FASCO, Prof Med, Vice Chair Taussig Cancer Ctr, Dir GI Cancers, @ClevelandClinic. Writer. Opinions my own. I have #FCOI.

Featured in: Favicon

tandfonline.com Favicon

wiley.com (+1) Favicon

bmj.com

jamanetwork.com Favicon

dawn.com

thelancet.com Favicon

thewire.in Favicon

medpagetoday.com Favicon

cantonrep.com Favicon

healio.com + 105 more

Articles

A Deeply Globalized Ancient World: On William Dalrymple’s The Golden Road

1 month ago | lithub.com | Alok Khorana

It was my first visit to Tokyo. Thanks to a lost-in-translation miscommunication with my scientific colleagues, I found myself with an unexpectedly open daytime schedule. This is how I ended up alone at the Tokyo National Museum one brisk fall weekday morning in 2019, in front of a group of 5th century CE sculptures with what seemed to my uneducated eye to be distinctly Indian aesthetics: upraised palms, multiple arms, lotus symbols.
Overview of the CheckMate 8HW Study

Feb 6, 2025 | targetedonc.com | Rahul Gosain |Rohit Gosain |Alok Khorana

Experts discuss the CheckMate 8HW study, focusing on its design, key findings, and impact on treatment strategies.
Overview of the BREAKWATER Study

Feb 6, 2025 | targetedonc.com | Rahul Gosain |Rohit Gosain |Alok Khorana

Experts discuss an overview of the BREAKWATER study, highlighting its key objectives, findings, and implications.
Overview of the STARTER-NET Study

Feb 6, 2025 | targetedonc.com | Rahul Gosain |Rohit Gosain |Alok Khorana

Experts discuss an overview of the STARTER-NET study, emphasizing its goals, key outcomes, and potential impact on clinical practice.
VTE incidence shortens survival in IDH-WT glioblastoma

Jan 9, 2025 | medrxiv.org | Anthony Sloan |Alan J. Gordillo |Austin Kennemer |Alok Khorana

The author declare no conflicts of interest. JDL is listed as an inventor on intellectual property related to cancer therapies, but this is not directly relevant to this work. This work is supported by a cancer biology training grant NIH T32 CA059366 (To ARS), Ruth L. Kirschstein Postdoctoral NRSA NIH F32 CA287655 (To ARS), and the Midwest Brain Tumor Foundation Postdoctoral Fellowship (To ARS), NIH HL158801 (to SJC).
Tumor microbiome differences in early-onset versus

May 28, 2024 | newswise.com | Alok Khorana

Newswise — The rise in early-onset gastrointestinal cancers includes an increased risk of pancreatic adenocarcinoma (PDAC), but the underlying pathogenesis is incompletely understood. The tumor microbiome is an increasing focus of research given its impact on tumor pathogenesis and outcomes. We evaluated microbiome profiles in resected specimens from early-onset PDAC (eoPDAC) and average-onset PDAC (aoPDAC).
Management of venous thromboembolism in patients with active cancer

Feb 1, 2024 | ccjm.org | Heloni Dave |Alok Khorana

KEY POINTS Patients with cancer are at a much higher risk of developing VTE than the general population. Low-molecular-weight heparin or direct oral anticoagulants are preferred over vitamin K antagonists. Direct oral anticoagulants are generally preferred, but caution is needed in patients at risk of bleeding.
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Dec 15, 2023 | cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more

December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Dec 15, 2023 | cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more

December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Dec 15, 2023 | cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more

December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.